NASDAQ · Biotechnology

MGNX (MGNX) Stock

$3.78 +3.00% NASDAQ: MGNX Healthcare

Valuation

MetricValue
Price$3.78
Market Cap$240.27M
P/E Ratio-2.92
P/B Ratio12.35
P/S Ratio1.67
EPS (TTM)$-1.33
52-Week High$5.03
52-Week Low$1.19
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-140.27%
ROA-17.98%
ROCE-130.36%
Gross Margin69.93%
Operating Margin-40.53%
Net Margin-44.79%
Debt/Equity1.72
Current Ratio5.12

Annual Financials (USD)

Metric20212022202320242025
Revenue$76.0M$150.0M$57.0M$148.0M$150.0M
Operating Profit$-203.0M$-121.0M$-168.0M$-111.0M$-73.0M
Net Profit$-202.0M$-120.0M$-9.0M$-67.0M$-75.0M
EPS$-3.18$-1.95$-0.15$-1.07$-1.18
Op Margin-268.1%-80.9%-294.2%-74.5%-48.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$335.0M$290.0M$298.0M$262.0M$257.0M
Total Liabilities$96.0M$147.0M$146.0M$146.0M$201.0M
Cash$123.0M$109.0M$101.0M$183.0M$57.0M
Borrowings$25.0M$35.0M$34.0M$37.0M$107.0M

Latest News

R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy Insider Monkey · Jul 5, 2026 VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone Exec Edge · Jul 2, 2026 MacroGenics Closes Sale of Manufacturing Operations to Bora Pharmaceuticals MT Newswires · Jul 2, 2026 MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy? Zacks · Jul 2, 2026 Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operations ACCESS Newswire · Jul 2, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-144.0M$-87.0M$-78.0M$-68.0M$-81.0M
Investing Cash Flow$-43.0M$67.0M$-82.0M$146.0M$-116.0M
Financing Cash Flow$5.0M$1.0M$149.0M$1.0M$69.0M
Net Cash Flow$-58.0M$-15.0M$-8.0M$82.0M$-126.0M
Free Cash Flow$-150.0M$-91.0M$-80.0M$-72.0M$-83.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-2.37
FCF Yield-27.32%
Quick Ratio1.80
Interest Coverage-8.11
Return 1Y121.55%
Return 3Y-16.98%
Return 5Y-82.60%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLNNClene Inc. $5.29 -1.86% -1.66 $54.53M 0.00%
CNTB $2.07 -1.67% -2.31 $130.02M 0.00%
CNTX $0.62 +4.47% -6.84 $56.69M 0.00%
COYA $4.00 -6.21% -2.62 $72.84M 0.00%
IFRX $1.84 +6.98% -4.16 $132.91M 0.00%

About MGNX

MGNX is led by CEO Eric Blasius Risser, publicly traded since 2013.

MGNX stock trades at $3.78 with a market capitalization of $240.27M. The stock is valued at a price-to-earnings (P/E) ratio of -2.92, price-to-book of 12.35, price-to-sales of 1.67. Over the past 52 weeks the stock has ranged between $1.19 and $5.03, and currently trades 24.9% below its 52-week high.

On profitability, MGNX generates a return on equity (ROE) of -140.27%, return on capital employed of -130.36%, an operating margin of -40.53%, a net profit margin of -44.79%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides